The rationale for the use of anti-BAFF therapy in human SLE is evident from several preclinical studies... Belimumab, a humanized antibody against B-cell-activating factor (BAFF, also known as ...

Aberrant B-cell function, which could arise from various underlying causes, is central to the pathogenesis of diverse ...

Signaling through BAFF-R and BCMA increases the levels of the ... clinical trials and appear well tolerated. Their efficacy in SLE is unknown at present. [58–59] ...

also known as TNFSF13B and BAFF), developed by Human Genome Sciences and GlaxoSmithKline, met the primary end point in a Phase III trial for systemic lupus erythematosus (SLE). If approved ...

which are thought to be central to the disease process in SLE although the precise cause of the disease is unknown. Benlysta binds and neutralises the B cell survival factor BAFF, while rituximab ...

Alpine is also developing acazicolcept (formerly ALPN-101) in a mid-stage study for systemic lupus erythematosus (SLE) in collaboration ... which also targets both BAFF and APRIL, as a treatment ...